16 Dec
2016
16:30 E.S.T.

Cellectis Announces Conference Call To Discuss Recent Recombinant DNA Advisory Committee (RAC) Meeting

Read more

15 Dec
2016
16:30 E.S.T.

Cellectis Announces Recombinant DNA Advisory Committee’s (RAC) Unanimous Approval of UCART123 Phase 1 Study Protocols in AML and BPDCN

Read more

22 Nov
2016
16:30 E.S.T.

Cellectis Reports Financial Results for 3rd Quarter and First Nine Months 2016

Read more

21 Nov
2016
16:30 E.S.T.

Cellectis to Participate in Oppenheimer Life Sciences Summit, NY & in Piper Jaffray 28th Annual Health Care Conference, NY

Read more

15 Nov
2016
16:30 E.S.T.

Cellectis Announces Successful cGMP Manufacturing for Second Product Candidate: UCART123

Read more

31 Oct
2016
16:30 E.S.T.

Cellectis Hosts World’s First Gene Edited Dinner in NYC

Read more

04 Oct
2016
16:30 E.S.T.

Cellectis Announces the Issuance of U.S. Patent 9,458,439 Following U.S. Patent 8,921,332 Issued in December 2014

Read more

28 Sep
2016
16:30 E.S.T.

Cellectis Wins 2016 Most Innovative European Biotech SME Award for Healthcare

Read more

09 Sep
2016
16:30 E.S.T.

Cellectis Reports 2nd Quarter and First Half Year 2016 Financial Results

Read more

27 Jun
2016
16:30 E.S.T.

MIT Technology Review Names Cellectis on Annual List of 50 Smartest Companies for Second Consecutive Year

Read more